Clinical Trial Update: Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT) [Phase 2]

View source ↗

Summary

Phase 2 trial update for a four-drug regimen (gemcitabine, nab-paclitaxel, lenalidomide, and tislelizumab) in advanced unresectable biliary tract cancer, includ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Gallbladder Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Lenalidomide (lenalidomide)
• Nab-paclitaxel (paclitaxel protein-bound)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Wei Gong | Conditions: Gallbladder Cancer, Cholangiocarcinoma | Phase 2 | Status: ENROLLING_BY_INVITATION